sábado, 1 de diciembre de 2018

An FDA approval could come at a major cost for patients

An FDA approval could come at a major cost for patients



Daily Recap

‘A loss for the rest of us’: An FDA approval is a boon for a drug maker, but could come at a major cost for patients

By MEGHANA KESHAVAN


DOM SMITH/STAT
A Florida-based drug maker now has the ability to charge a premium on a drug that has come free or dirt cheap for many patients for decades.

No hay comentarios: